NCT02168738 - Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules | Biotech Hunter

Enrollment

4

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Healthy Subject

Interventions

DRUG

13-C labeled AceDoPC-DHA

"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"

DRUG

13-C labeled TG-DHA

"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"

DRUG

13-C labeled PC-DHA

"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"

Trial Locations (1)

69310

Centre de Recherche en Nutrition Humaine Rhône-Alpes, 165 chemin du Grand Revoyet,, Pierre-Bénite